Adagene Achieves $3M Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked ADC May 5, 2025
Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals April 30, 2025
FDA clears IND application for VS-7375, Enabling Ph 1/2a Trial in Advanced Solid Tumors April 30, 2025
Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of TCR-NK Therapy ZI-MA4-1 Targeting Solid Tumours April 30, 2025
Veraxa and Voyager to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Gen Cancer Therapies April 30, 2025
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers April 30, 2025
NMPA accepted NDA for zurletrectinib (ICP-723) for patients with advanced solid tumors harboring NTRK gene fusions April 22, 2025
First Patient Treated in Ph 1 Trial of PHST001 for Patients with Advanced Solid Tumors April 22, 2025
US FDA Grants Full Approval of VITRAKVI (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors April 16, 2025
Edity Therapeutics and Aurigene Oncology to Advance a Novel Cell Therapy Program for Solid Tumors April 8, 2025
FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies April 8, 2025
Boehringer Ingelheim strengthens ADC portfolio with new NBE Therapeutics R&D center in Basel April 8, 2025
FDA clears IND application for ALX2004 for the treatment of EGFR-expressing solid tumors April 8, 2025
